FR3107648B1 - conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie - Google Patents

conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie Download PDF

Info

Publication number
FR3107648B1
FR3107648B1 FR2001974A FR2001974A FR3107648B1 FR 3107648 B1 FR3107648 B1 FR 3107648B1 FR 2001974 A FR2001974 A FR 2001974A FR 2001974 A FR2001974 A FR 2001974A FR 3107648 B1 FR3107648 B1 FR 3107648B1
Authority
FR
France
Prior art keywords
antibody
therapy
drug conjugates
conjugates
drug
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR2001974A
Other languages
English (en)
Other versions
FR3107648A1 (fr
Inventor
Ludovic Juen
Christine Baltus
Audrey Desgranges
Antoine Touzé
Thibault Kervarrec
Valérie Leblond
Mahtab Samimi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mcsaf Inside Oncology Fr
Original Assignee
Mc Saf
Centre Hospitalier Regional Universitaire de Tours
Universite de Tours
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR2001974A priority Critical patent/FR3107648B1/fr
Application filed by Mc Saf, Centre Hospitalier Regional Universitaire de Tours, Universite de Tours filed Critical Mc Saf
Priority to US17/802,274 priority patent/US20230144142A1/en
Priority to PCT/FR2021/050332 priority patent/WO2021170961A1/fr
Priority to CA3166699A priority patent/CA3166699A1/fr
Priority to JP2022552310A priority patent/JP2023515845A/ja
Priority to EP21714002.9A priority patent/EP4110405A1/fr
Priority to CN202180017269.9A priority patent/CN115515642A/zh
Priority to AU2021227413A priority patent/AU2021227413A1/en
Publication of FR3107648A1 publication Critical patent/FR3107648A1/fr
Application granted granted Critical
Publication of FR3107648B1 publication Critical patent/FR3107648B1/fr
Priority to US18/333,261 priority patent/US20230405140A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6865—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from skin, nerves or brain cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie L’invention concerne des conjugués anticorps-médicament, et leur utilisation en thérapie, notamment pour traiter les cancers CD56+.
FR2001974A 2020-02-27 2020-02-27 conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie Active FR3107648B1 (fr)

Priority Applications (9)

Application Number Priority Date Filing Date Title
FR2001974A FR3107648B1 (fr) 2020-02-27 2020-02-27 conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie
PCT/FR2021/050332 WO2021170961A1 (fr) 2020-02-27 2021-02-26 Conjugués anticorps-médicament anti-cd56 et leur utilisation en thérapie
CA3166699A CA3166699A1 (fr) 2020-02-27 2021-02-26 Conjugues anticorps-medicament anti-cd56 et leur utilisation en therapie
JP2022552310A JP2023515845A (ja) 2020-02-27 2021-02-26 抗－ｃｄ５６抗体－薬物複合体およびその治療での使用
US17/802,274 US20230144142A1 (en) 2020-02-27 2021-02-26 Anti-cd56 antibody-drug conjugates and their use in therapy
EP21714002.9A EP4110405A1 (fr) 2020-02-27 2021-02-26 Conjugués anticorps-médicament anti-cd56 et leur utilisation en thérapie
CN202180017269.9A CN115515642A (zh) 2020-02-27 2021-02-26 抗cd56抗体-药物偶联物及其在治疗中的用途
AU2021227413A AU2021227413A1 (en) 2020-02-27 2021-02-26 Anti-CD56 antibody-drug conjugates and their use in therapy
US18/333,261 US20230405140A1 (en) 2020-02-27 2023-06-12 Anti-cd56 antibody-drug conjugates and their use in therapy

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR2001974A FR3107648B1 (fr) 2020-02-27 2020-02-27 conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie
FR2001974 2020-02-27

Publications (2)

Publication Number Publication Date
FR3107648A1 FR3107648A1 (fr) 2021-09-03
FR3107648B1 true FR3107648B1 (fr) 2022-03-18

Family

ID=71894885

Family Applications (1)

Application Number Title Priority Date Filing Date
FR2001974A Active FR3107648B1 (fr) 2020-02-27 2020-02-27 conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie

Country Status (8)

Country Link
US (2) US20230144142A1 (fr)
EP (1) EP4110405A1 (fr)
JP (1) JP2023515845A (fr)
CN (1) CN115515642A (fr)
AU (1) AU2021227413A1 (fr)
CA (1) CA3166699A1 (fr)
FR (1) FR3107648B1 (fr)
WO (1) WO2021170961A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3131835A1 (fr) * 2022-01-17 2023-07-21 Mc Saf Procédé de préparation de conjugués anticorps-médicament
FR3131836A1 (fr) * 2022-01-17 2023-07-21 Mc Saf Conjugués anticorps-médicament pour utilisation thérapeutique
WO2024040194A1 (fr) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditionnement pour l'ingénierie de cellules immunitaires in vivo

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3008408B1 (fr) * 2013-07-11 2018-03-09 Mc Saf Nouveaux conjugues anticorps-medicament et leur utilisation en therapie
US10548987B2 (en) 2015-07-31 2020-02-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Antibody-drug conjugates for targeting CD56-positive tumors
CN107744592B (zh) * 2017-09-15 2020-04-28 四川大学 抗cd56抗体与海兔毒素偶联复合物及其制备方法和用途
CN107715119B (zh) * 2017-09-15 2020-11-10 四川大学 抗cd56抗体与多卡霉素偶联复合物及其制备方法和用途

Also Published As

Publication number Publication date
CA3166699A1 (fr) 2021-09-02
WO2021170961A1 (fr) 2021-09-02
AU2021227413A1 (en) 2022-10-20
US20230405140A1 (en) 2023-12-21
JP2023515845A (ja) 2023-04-14
FR3107648A1 (fr) 2021-09-03
EP4110405A1 (fr) 2023-01-04
US20230144142A1 (en) 2023-05-11
CN115515642A (zh) 2022-12-23

Similar Documents

Publication Publication Date Title
PH12020551923A1 (en) Methods and compositions for treating cancer
FR3107648B1 (fr) conjugués anticorps-médicament anti-CD56 et leur utilisation en thérapie
MX2021007790A (es) Inhibidores de idh2 para el tratamiento de neoplasias malignas hematologicas y tumores solidos.
PH12019501663A1 (en) Anti-gpr20 antibody and anti-gpr20 antibody-drug conjugate
FR3096259B1 (fr) conjugués anticorps-médicament et leur utilisation en thérapie
EA201891607A1 (ru) Axl-специфичные конъюгаты антитело-лекарственное средство для лечения злокачественных новообразований
MX2018015683A (es) Composiciones y métodos para el agotamiento de células.
MD3362065T2 (ro) Terapie combinată care conține ivosidenib, citarabină și daunorubicina sau idarubicina pentru tratarea leucemiei acute mielogene
MA43000B1 (fr) Polythérapie pour le traitement de tumeurs malignes
TN2016000094A1 (en) Inhibitors of bruton's tyrosine kinase.
NO20054988D0 (no) Preparater og metoder for behandling av cancer
MX2020006654A (es) Métodos intraductales de tratamiento de trastornos de mama.
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
MX2021009138A (es) Anticuerpos anti-cd228 y conjugados de anticuerpo-farmaco.
CR20210573A (es) Moléculas de unión a tigit y pd-1 / tigit
BR112021025699A2 (pt) Anticorpos anti-mesotelina e imunoconjugados dos mesmos
PH12021551047A1 (en) Anti-ptk7 immune cell cancer therapy
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
MA33091B1 (fr) Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers specifiques
PH12020551556A1 (en) Drug conjugates of cmet monoclonal binding agents, and uses thereof
FR2945210B1 (fr) Combinaison antitumorale comprenant l'ave8062 et le sorafenib
HK1076055A1 (en) Covalent conjugates between artemisinin-related endoperoxides and iron- carrying proteins and methods of use
MX2022013402A (es) Combinaciones antitumorales que contienen productos conjugados de anticuerpos anti-ceacam5 y folfiri.
MX2022014231A (es) Conjugados de anticuerpo-farmaco que se enfocan a la uparap.
FR3101541B1 (fr) conjugués anticorps-médicament et leur utilisation en thérapie

Legal Events

Date Code Title Description
PLFP Fee payment

Year of fee payment: 2

PLSC Publication of the preliminary search report

Effective date: 20210903

PLFP Fee payment

Year of fee payment: 3

TP Transmission of property

Owner name: MC SAF, FR

Effective date: 20211014

TP Transmission of property

Owner name: MCSAF INSIDE ONCOLOGY, FR

Effective date: 20220822

PLFP Fee payment

Year of fee payment: 4

PLFP Fee payment

Year of fee payment: 5